Altimmune Inc
ALT
Company Profile
Business description
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Contact
910 Clopper Road
Suite 201S
GaithersburgMD20878
USAT: +1 240 654-1450
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
59
Altimmune Inc News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,184.20 | 27.30 | -0.30% |
| CAC 40 | 8,314.92 | 16.04 | -0.19% |
| DAX 40 | 25,286.29 | 0.05 | 0.00% |
| Dow JONES (US) | 49,149.63 | 42.36 | -0.09% |
| FTSE 100 | 10,233.61 | 49.26 | 0.48% |
| HKSE | 26,923.62 | 76.19 | -0.28% |
| NASDAQ | 23,471.75 | 238.13 | -1.00% |
| Nikkei 225 | 54,110.50 | 230.73 | -0.42% |
| NZX 50 Index | 13,659.79 | 97.92 | -0.71% |
| S&P 500 | 6,926.60 | 37.14 | -0.53% |
| S&P/ASX 200 | 8,861.70 | 19.30 | -0.22% |
| SSE Composite Index | 4,112.60 | 13.49 | -0.33% |